Ponsegromab

Last updated
Ponsegromab
Monoclonal antibody
Type ?
Target GDF-15
Clinical data
Other namesPF-06946860
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Ponsegromab (PF-06946860) is a monoclonal antibody that works as a GDF-15 inhibitor. It is developed by Pfizer for cancer cachexia. [1] [2] [3] [4] [5]

In September 2024, Pfizer disclosed that ponsegromab led to significant body weight increases in patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer in a phase 2 clinical trial. [6]

References

  1. ↑ Nishie, Kenichi; Nishie, Tomomi; Sato, Seiichi; Hanaoka, Masayuki (September 2023). "Update on the treatment of cancer cachexia". Drug Discovery Today. 28 (9): 103689. doi: 10.1016/j.drudis.2023.103689 . PMID   37385369. S2CID   259294809.
  2. ↑ Roeland, E.J.; Yennu, S.; Del Fabbro, E.; Buckeridge, C.; Thayer, K.M.; Collins, S.M.; Lubaczewski, S.L.; Wang, E.Q.; Calle, R.A. (September 2021). "1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer". Annals of Oncology. 32: S1185. doi: 10.1016/j.annonc.2021.08.1668 .
  3. ↑ Crawford, Jeffrey; Lubaczewski, Shannon L; Tarachandani, Anil; Harrington, Magdalena A; Weng, Yan; Qiu, Ruolun; Collins, Susie M; Rossulek, Michelle I; Revkin, James H (1 June 2023). "Phase 2 study to assess the efficacy, safety, and tolerability of the GDF-15 inhibitor ponsegromab in patients with cancer cachexia". Journal of Clinical Oncology. 41 (16_suppl): TPS12147. doi:10.1200/JCO.2023.41.16_suppl.TPS12147.
  4. ↑ Crawford, Jeffrey; Calle, Roberto A.; Collins, Susie M.; Weng, Yan; Lubaczewski, Shannon L.; Buckeridge, Clare; Wang, Ellen Q.; Harrington, Magdalena A.; Tarachandani, Anil; Rossulek, Michelle I.; Revkin, James H. (14 April 2023). "Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy". Cancer Research. 83 (8_Supplement): CT108. doi:10.1158/1538-7445.AM2023-CT108. S2CID   258165004.
  5. ↑ Talbert, Erin E.; Guttridge, Denis C. (May 2022). "Emerging signaling mediators in the anorexia–cachexia syndrome of cancer". Trends in Cancer. 8 (5): 397–403. doi: 10.1016/j.trecan.2022.01.004 . PMC   9035074 . PMID   35190301.
  6. ↑ "Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia | Pfizer". www.pfizer.com. Retrieved 2024-10-28.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.